特比奈芬乳膏治疗浅部真菌病80例临床疗效观察

目的 观察1%盐酸特比奈芬乳膏治疗浅部真菌病疗效及安全性.方法 以克霉唑霜为对照,采用随机对照临床试验方法治疗浅部真菌病160例,其中特比奈芬组80例,克霉唑组80例.患者随机接受1%盐酸特比奈芬乳膏和克霉唑霜治疗,均为每日2次.治疗结束后根据临床症状、体症、真菌镜检和培养评价临床疗效.结果 1%盐酸特比奈芬乳膏总有效率为91.2%;克霉唑霜总有效率为80.0%;真菌清除率1%盐酸特比奈芬乳膏为85.0%,克霉唑霜为71.3%.两种药物对改善患者症状体征均有效,1%盐酸特比奈芬乳膏疗效优于克霉唑霜(P＜0.05).结论 1%盐酸特比奈芬乳膏治疗浅部真菌病疗效好、安全性好.     

盐酸布替萘芬乳膏治疗浅部真菌病的疗效观察

目的 :探讨盐酸布替萘芬乳膏治疗浅部真菌病的疗效和安全性。方法 :采用随机、对照的临床研究方法 ,对 6 0例浅部真菌病患者进行分组 ,试验组以盐酸布替萘芬乳膏外用 ,对照组采用特比萘芬乳膏外用 ,观察用药 3周的临床疗效。结果 :用药后 3周试验组和对照组的有效率分别为 83.33%和 80 .0 0 %。试验组略高于对照组 ,但差异无显著性。结论 :盐酸布替萘芬乳膏治疗浅部真菌病快速、安全、有效。     

特比萘芬软膏治疗浅部真菌病91例

目的 :观察特比萘芬软膏治疗浅部真菌病的疗效。方法 :91例皮肤浅部真菌病人应用特比萘芬软膏外涂患处 ,bid ,体、股癣连用 2wk ,手、足癣连用 3wk。结果 :91例皮肤浅部真菌病病人 ,痊愈 58例 ,显效 2 7例 ,临床治愈率 6 4 % ,显效率为 94 % ,真菌学治愈率 10 0 %。未见不良反应。结论 :特比萘芬软膏治疗皮肤浅部真菌病疗效可靠 ,无不良反应。     

特比萘芬治疗真菌病现状

特比萘芬是一种丙烯胺类的抗真菌药物 ,具有广谱抗真菌活性 ,临床上有口服和外用制剂。广泛用于治疗浅部真菌病 ,结果显示特比萘芬治疗浅部真菌病疗程短、疗效高、不良反应少、复发率低。尤其对甲真菌病进行短程连续疗法、冲击疗法、短程隔日疗法比较 ,以短程连续疗法疗效最好。对由皮肤癣菌引起的甲真菌病特比萘芬比灰黄霉素、伊曲康唑和氟康唑疗效要好。除此之外 ,特比萘芬还有效治疗了一些曲霉病、孢子丝菌病和着色芽生菌病。     

特比萘芬软膏治疗小儿皮肤浅部真菌病72例

目的 :观察国产特比萘芬软膏治疗小儿皮肤浅部真菌病的疗效与安全性。方法 :小儿皮肤浅部真菌病病人 72例 ,男性 38例 ,女性 34例 ,年龄 3a±s 3a ,病程 2mo± 2mo ,其中皮肤念珠菌病 32例 ,体、股癣 2 5例 ,手、足癣 12例 ,花斑癣 3例。用该软膏搽患处 ,每日 2次 ,疗程 2wk。结果 :72例病人总痊愈率 90 % ,总有效率 97% ,总真菌清除率92 % ,不良反应发生率 3%。结论 :国产特比萘芬软膏为治疗小儿皮肤浅部真菌病新的有效、安全外用药物。     

特比萘芬软膏治疗浅部皮肤真菌病124例

目的 :观察特比萘芬软膏对体、股癣 ,花斑癣及手、足癣的治疗作用。方法 :浅部真菌病人 12 4例 ,其中体、股癣 6 8例 ;花斑癣 11例 ;手、足癣 4 5例。男性 72例 ,女性 52例 ,年龄 4 1a±s 14a。外用 1%特比萘芬软膏涂药 ,每日 2次 ,体、股癣用药7d ,花斑癣 ,手、足癣用药 14d。结果 :特比萘芬软膏治疗皮肤浅部真菌病总痊愈率为 73.0 % ,总有效率为 87.0 %。结论 :特比萘芬软膏是治疗皮肤浅部真菌病安全有效的药物。     

生物溶菌酶加特比萘芬治疗小儿鹅口疮80例疗效观察

目的:观察生物溶菌酶配合特比萘芬治疗小儿鹅口疮的临床疗效。方法:将80例患儿随机分为观察组和对照组,每组各40例。观察组局部外用生物溶菌酶喷雾剂(商品名:新净界)并配以盐酸特比奈芬喷雾剂治疗,对照组单独局部外用盐酸特比奈芬喷雾剂治疗,1个疗程后观察疗效。结果:观察组疗效明显优于对照组(P<0.01)。结论:生物溶菌酶配合盐酸特比奈芬喷雾剂治疗小儿鹅口疮起效快,可缩短疗程,又不影响患儿容貌外观,家属易于接受。     

三种治疗甲真菌病药物的成本——效果分析

目的：探讨3种抗真菌药（伊曲康唑、特比奈芬、氟康唑）治疗甲真菌病的经济效果,找出既经济又有效的治疗方案。方法：根据文献选择3种不同的治疗方案（伊曲康唑组、特比奈芬组、氟康唑组）,应用药物经济学成本-效果分析法。结果：治疗指甲真菌病所需药品成本分别是666.68,634.42,459.96元;治疗趾甲真菌病所需的药品成本分别是1000.02,911.98,689.94元。远期治愈率指甲真菌病分别是94.4%,100.0%和77.8%;趾甲真菌病分别是86.4%,95.2%和68.2%。结论：根据药物经济学成本-效果分析,特比奈芬是治疗甲真菌病的最佳药物。     

特比萘芬治疗皮肤浅部真菌病80例

目的 :观察特比萘芬软膏对皮肤浅部真菌病的临床疗效和不良反应。方法 :皮肤浅部真菌病的病人 80例 (男性 51例 ,女性 2 9例 ,年龄 4 1a±s17a) ,全部病人真菌镜检阳性 ,并对其中 30例做真菌培养 ,给予国产特比萘芬软膏外用 ,每日 2次 ,体、股癣及花斑癣治疗 1wk ,手、足癣治疗 2wk。结果 :停药后 2wk临床有效率 :体癣 10 0 % ,股癣 10 0 % ,手癣 10 0 % ,足癣 86 % ,花斑癣 10 0 % ,临床总有效率为 99%。真菌清除率 :体癣 94 % ,股癣 95% ,手癣 10 0 % ,足癣 86 % ,花斑癣 90 % ,总清除率为 94%。全部病例未见明显不良反应。结论 :国产特比萘芬软膏治疗皮肤部真菌病疗效佳 ,不良反应少。     

国产特比萘芬软膏与进口特比萘芬软膏对照治疗浅部真菌病

目的 :比较国产和进口 1%特比萘芬软膏治疗浅部真菌病的疗效和安全性。方法 :50例国产特比萘芬试验组中男性 2 7例 ,女性 2 3例 ,年龄 38a±s 17a ;进口特比萘芬对照组中男性 2 5例 ,女性2 3例 ,年龄 39a± 17a。 2种药物的用药剂量和疗程相同 ,外涂患处 ,每日 2次 ,体、股癣 ,花斑癣用药1wk为一个疗程 ,手、足癣和皮肤念珠菌病用药 2wk为一个疗程。结果 :国产特比萘芬软膏治疗浅部真菌病 ,临床有效率为 96 % ,真菌清除率为 90 % ,不良反应发生率为 2 % ;进口特比萘芬软膏治疗浅部真菌病 ,临床有效率为 98% ,真菌清除率为92 % ,不良反应发生率为 2 %。 2种药物治疗浅部真菌病的临床疗效和安全性经统计学处理差异均无显著意义 (P >0 .0 5)。结论 :国产与进口特比萘芬软膏治疗浅部真菌病有相似疗效及安全性。     

Terbinafine. An update of its use in superficial mycoses.

Terbinafine is an allylamine antifungal agent which has fungicidal activity against a wide variety of dermatophytes, moulds and certain dimorphic fungi, and fungistatic activity against Candida albicans. Oral terbinafine 250 mg/day is effective in the treatment of superficial dermatophyte infections such as onychomycosis, tinea pedis and tinea corporis/cruris, generally achieving mycological cure in > 80% of patients. The drug is also effective in children with tinea capitis when administered orally in the dosage range 62.5 to 250 mg/day for 4 weeks. Comparative data indicate that oral terbinafine is more effective than continuous or intermittent intraconazole in dermatophyte onychomycosis, and is as effective as itraconazole 400 mg/day in tinea pedis. The drug has shown greater efficacy than griseofulvin in dermatophyte onychomycosis, tinea pedis and tinea corporis/cruris, and comparable efficacy in children with tinea capitis. Additionally, oral terbinafine is more effective than ketoconazole 200 mg/day in tinea corporis/cruris. Topical terbinafine 1% formulations are effective when applied once or twice daily for up to 2 weeks, achieving mycological cure in > 80% of patients with tinea pedis, tinea corporis/cruris, cutaneous candidiasis and pityriasis versicolor. Its formulations are at least as effective as miconazole 2% cream and naftifine 1% gel in tinea pedis, and more effective than clotrimazole 1% cream, bifonazole 1% cream and oxiconazole 1% lotion. Mycological cure rates achieved with terbinafine generally improve after treatment cessation, reflecting the drug's fungicidal mechanism of action and its residual effect in tissue. Terbinafine is well tolerated after oral or topical administration and has a relatively low potential for drug interactions. Pharmacoeconomic data support the use of terbinafine in dermatophyte infections of the skin or nails. CONCLUSIONS: Evidence suggests that oral terbinafine is the treatment of choice for dermatophyte onychomycosis, as it achieves high rates of mycological and clinical cure, is generally well tolerated and has a relatively low potential for drug interactions. It must also be considered a first-line treatment option, along with itraconazole, in cutaneous mycoses which warrant systemic treatment; topical terbinafine is a treatment of choice in less extensive mycoses. The use of terbinafine in non-dermatophyte or mixed infections has not been fully defined.     

Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses.

Terbinafine is an orally and topically active allylamine antifungal agent with a primarily fungicidal action in vitro. Its spectrum of in vitro activity includes a broad range of dermatophyte, filamentous, dimorphic and dematiaceous fungi, and some yeast species. In clinical trials, mycological and overall efficacy rates of around 90 and 80%, respectively, have been achieved in cutaneous dermatophyte infections (tinea corporis/cruris and tinea pedis) with terbinafine, administered either orally (250 or 500 mg/day) or topically (a 1% cream applied twice daily). Similar rates of cure have been obtained with oral terbinafine in dermatophyte nail infections after relatively short treatment periods ranging from 3 to 12 months. Topical terbinafine has been effective in approximately 80% of patients with cutaneous candidiasis or pityriasis versicolor. Few comparative data have been published, but generally oral terbinafine appeared to be at least as effective as oral griseofulvin or ketoconazole in tinea corporis/cruris and more effective than griseofulvin in tinea pedis. Both oral and topical terbinafine have been very well tolerated in clinical trials to date, with only minor adverse effects reported. Although further research is required to establish the efficacy of terbinafine in comparison with other available therapies, as well as to fully clarify its tolerability profile, the early results obtained with terbinafine in superficial fungal infections are very encouraging. Terbinafine appears likely to become a first-line therapy for dermatophyte infections, particularly those affecting the nails.     

盐酸特比萘芬软膏治疗浅部真菌病36例临床研究

目的探讨盐酸特比萘芬乳膏对皮肤浅部真菌感染的治疗效果。方法皮肤浅部真菌病患者被分成人数相同的治疗组与对照组,治疗组使用盐酸特比萘芬软膏治疗,对照组使用克霉唑软膏进行治疗,并对比两组的疗效。结果观察组总有效率为100.0%,对照组总有效率为83.3%。观察组的总有效率高于对照组。结论 1%盐酸特比萘芬乳膏对皮肤浅部真菌感染的治疗效率好,安全性高,值得推广。     

Fungicidal activity plus reservoir effect allow short treatment courses with terbinafine in tinea pedis

Terbinafine, a synthetic allylamine, exerts fungicidal activity against dermatophytes, the causative pathogens of tinea pedis. As proven in numerous clinical trials, tinea pedis can be effectively and safely treated by topical terbinafine. In fact, a 1-week application of terbinafine 1% cream eradicated fungal pathogens at least as effectively as 4-week treatment courses with topical azole derivative antifungals and showed lower relapse rates. A new innovative single-application formulation of terbinafine 1% in a film-forming solution produces a high concentration gradient on the skin surface and enables a prolonged (up to 13 days) exposure of the skin to terbinafine. High drug penetration into the skin results in an otherwise not obtained drug reservoir in the horny layer, the location of dermatophytes in tinea pedis. Although azole antimycotics can also effectively penetrate into the horny layer of the skin, short-term therapy might not be feasible due to its primarily fungistatic activity against dermatophytes. Thus, we conclude that the high efficacy of short-term treatment with terbinafine in patients with tinea pedis is possible due to its fungicidal activity coupled with a distinct reservoir formation in the upper layers of the epidermis.     

两种盐酸特比萘芬乳膏治疗浅表真菌病临床疗效对比

目的评价两种盐酸特比萘芬乳膏(商品名分别为兰美抒乳膏和丁克乳膏)治疗浅表真菌病的疗效和安全性。方法200例浅表真菌病患者随机分为两组。A组外用兰美抒乳膏。B组外用丁克乳膏。均每日2次。体股癣疗程2周,手足癣疗程4周。结果兰美抒组总有效率为85.0%,真菌清除率为100%。丁克组总有效率为83.0%,真菌清除率为98.0%,两组均无不良反应。结论两种盐酸特比萘芬乳膏疗效和安全性比较无显著性差异。     

特比萘芬软膏治疗浅部真菌病临床试验

目的 :评价特比萘芬软膏治疗浅部真菌病的疗效和安全性。方法 :2 0 2例浅部真菌病病人 (男性 12 7例 ,女性 75例 ;年龄 36a±s 12a)用特比萘芬软膏均匀涂布患处bid。体、股癣 ,花斑癣治疗 1wk ;鳞屑水疱型手、足癣治疗 2wk ;鳞屑角化型手、足癣治疗 4wk。结果 :总有效率为 91.1% ,真菌清除率 95.5%。不良反应发生率 2 %。结论 :特比萘芬软膏治疗浅部真菌病疗效显著且安全。     

特比萘芬与咪康唑软膏治疗手、足癣的临床疗效比较

目的比较特比萘芬软膏与咪康唑软膏用于手、足癣的疗效。方法将81例手、足癣患者随机分为观察组44例和对照组37例。观察组外用特比萘芬软膏,对照组外用咪康唑软膏,比较2组停药时及停药4周后临床疗效及真菌培养情况。结果观察组停药时和停药4周后总有效率和真菌清除率均高于对照组,差异有统计学意义(P<0.05)。结论特比萘芬软膏治疗手、足癣的疗效更好、疗程更短。     

Ajoene in the topical short-term treatment of tinea cruris and tinea corporis in humans. Randomized comparative study with terbinafine.

Ajoene (CAS 92284-99-6), an organic trisulphur originally isolated from garlic, has an antimycotic activity which has been widely demonstrated both in vitro and in vivo. The objective of this work was to compare the safety and effectiveness of ajoene (0.6%, gel) with terbinafine (CAS 91161-71-6) (1%, cream) for the treatment of tinea corporis and tinea cruris. The patients selected were 60 soldiers with clinical and mycological diagnosis of either dermatophytosis. They were distributed at random in two treatment groups, one treated with ajoene at 0.6% and the other with terbinafine at 1%. All patients were evaluated clinically and mycologically 30 and 60 days after completion of the treatment, which was considered effective when clinical signs and symptoms had disappeared and the mycological cultures were negative. Thirty days after treatment, the percent healing rate was 77 and 75 for the groups treated with ajoene and terbinafine, respectively. Sixty days after treatment, the healing rate 73% and 71% for the groups treated with ajoene and terbinafine, respectively. These results and those obtained in previous studies confirm that ajoene is a new agent for the topic treatment of superficial mycoses, and for the first time show the therapeutic usefulness of an inhibitor of phospholipids biosynthesis in eukaryotes.